Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > u guys are crazy..............
View:
Post by baldstock on Sep 11, 2022 4:26pm

u guys are crazy..............

dont get me wrong i have 35,000 shares @ 0.29 cents..........
 
U guys target price is 3~4 dollars? lol

my target price is 1 dollars .......the reason was

YOFOTO bought shares @0.95 and i thought it will easily go above a dollar.

However, i was wrong and we are @ 0.09.................

ALSO

Company named "HIRONC" makes similar DERMAL INJECTOR which is alreay approved by FDA and export the products to USA. A company market cap is about 90 million in CAD. They make skin related meical device too so lets be conservative so HALF of 90 mill is conservative! (if DERMAL PRECISE approved by FDA for REPLICEL.)

So my target market cap is 45 million in cad. around 0.90~1 dollars.

I am skeptical about RCH-01 (its a lottery ticket)

I am aiming the dermal PRECISE device. I compared with a peer company and if it is approved.
I think it will be a 1 dollar. NOT 3 dollar.........

and we dont know how much warrants are there.

YOFOTO, MAINPOINTE, and SCHUTTE have all the warrants @ different price.
AVERAGE warrant price was around 0.30 according to 2021 annual report.
one of reason i bought @0.29.............
Comment by MetzGER on Sep 12, 2022 8:15am
How Can HIRONC make a Similar Dermal injector of Replicel had the Patent on that?
Comment by baldstock on Sep 12, 2022 1:45pm
I meant HIRONC have FDA approved hair transparent device. Dermal injector is not a new new thing......... https://hironic.com/p/easymo product name "easymo"
Comment by RPINVESTOR on Sep 13, 2022 8:23am
Baldstock:- I looked at the product description of easymo and it just seems to be a device used to move a hair follicle from one area of the scalp to another with possibly no scaring. If my understanding is accurate, comparing this product (an improvement on the current procedure) to game changers like RCH01 and Dermaprecise is like comparing apples to oranges.  The problem with Replicel ...more  
Comment by toniZ1 on Sep 13, 2022 8:35am
lol you compare the wrong things. this "easymo" device is something total different. "easymo" is a hair transplant device where the dermal injector is a device to inject liquids into the scalp and NOT hair grafts. anyways from my point of view the the dermal injector is nothing to get exicted about if it ever gets into the market... some weeks to go and we get a nice reward or ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities